An Update on Less Invasive and Endoscopic Techniques Mimicking the Effect of Bariatric Surgery by Froukje J. Verdam, Ruben Schouten, Jan Willem Greve, Ger H. Koek, Nicole D. Bouvy

“…Obesity (BMI 30–35 kg/m2) and its associated disorders such as type 2 diabetes, nonalcoholic fatty liver disease, and cardiovascular disease have reached pandemic proportions worldwide. …”
Get full text

The Use of Noninvasive Velacur® for Discriminating between Volunteers and Patients with Chronic Liver Disease: A Feasibility Study by Michael P. Curry, Edward Tam, Caitlin Schneider, Noha Abdelgelil, Tarek Hassanien, Nezam H. Afdhal

“…Background and Aims. Nonalcoholic fatty liver disease is the leading cause of chronic liver disease globally and can progress to cirrhosis, liver failure, and liver cancer. …”
Get full text

Liver diseases (<i>Review of the Seventeenth Russian Gastroenterological Week proceedings, October, 10–12, 2011, Moscow</i>) by I. V. Mayev, A. N. Kazyulin, Yu. A. Kucheryavy, Ye. A. Mayevskaya

“…The most of publications (70,5%) has been devoted to etiopathogenesis, features of clinical pattern, diagnostics and treatment of acute and chronic viral hepatitis (2542 patients), liver cirrhoses (1338 patients), non-alcoholic fatty liver disease (1145 patients), toxic liver diseases (834 patients) that indicates medical and social impact of these diseases. …”
Get full text

Nutrition Therapy for Liver Diseases Based on the Status of Nutritional Intake by Kenichiro Yasutake, Motoyuki Kohjima, Manabu Nakashima, Kazuhiro Kotoh, Makoto Nakamuta, Munechika Enjoji

“…The dietary intake of patients with nonalcoholic fatty liver disease (NAFLD) is generally characterized by high levels of carbohydrate, fat, and/or cholesterol, and these dietary patterns influence hepatic lipid metabolism in the patients. …”
Get full text

Triterpenoids from Chios Mastiha Resin Against MASLD—A Molecular Docking Survey by Nataša Milošević, Maja Milanović, Milica Medić Stojanoska, Varomyalin Tipmanee, Ilias Smyrnioudis, George V. Dedoussis, Nataša Milić

“…Non-alcoholic fatty liver disease (NAFLD) is the most common chronic liver disease without an approved pharmacological approach for its prevention/treatment. …”
Get full text

Platelet Counts and Liver Enzymes after Bariatric Surgery by Hans-Erik Johansson, Arvo Haenni, Björn Zethelius

“…Obesity is characterized by liver steatosis, chronic inflammation, and increased liver enzymes, that is, gamma-glutamyltransferase (GGT) and alanine aminotransferase (ALT), markers for nonalcoholic fatty liver disease (NAFLD) and liver fat content. Increased platelet counts (PCs) are associated with inflammatory conditions and are a valuable biomarker of the degree of fibrosis in NAFLD. …”
Get full text

Herbicide Widespread: The Effects of Pethoxamid on Nonalcoholic Fatty Liver Steatosis In Vitro by Anna Virginia Adriana Pirozzi, Antonietta Stellavato, Chiara Schiraldi, Mariateresa Giuliano

“…Due to similarities to glyphosate, we did look at the effect of pethoxamid on impaired liver cells HepG2, using a nonalcoholic fatty liver disease (NAFLD) cell model in vitro. Pethoxamid was cytotoxic starting at 1 ppm. …”
Get full text

Early disease detection expert system development: primary machining software applications and dependences by A. S. Serobabov, E. V. Chebanenko, L. A. Denisova, T. S. Krolevets

“…The article observes descriptive statistics tools for the biomedical information processing, clinical trials data on the nonalcoholic fatty liver disease (NAFLD). The primary machining software package structure which characterizes patienthood including the laboratory studies results, co-morbidity, patient’s physiological parameters is elaborated. …”
Get full text

Effects of natural products on macrophage immunometabolism: A new frontier in the treatment of metabolic diseases by Jiani Li, Chen Guo, Xiaofei Yang, Weinan Xie, Wenjing Mi, Chenglong Hua, Cheng Tang, Han Wang

“…Dysregulation of macrophage immunometabolism has been closely implicated in several metabolic diseases, including obesity, type 2 diabetes mellitus (T2DM), non-alcoholic fatty liver disease (NAFLD), hypertension, atherosclerosis, and gout, which positions macrophages as potential therapeutic targets. …”
Get full text

Liver fibrosis and markers of endothelial function at metabolic syndrome and early disorders of carbohydrate metabolism by L. V. Chesnokova, I. M. Petrov, Ye. A. Sidorova, I. A. Troshina, Yu. A. Petrova

“…Complex estimation of endothelial function at non-alcoholic fatty liver disease (NAFLD) in association with early disorders of carbohydrate metabolism, in relation to liver fibrosis severity.Material and methods. …”
Get full text

Incidence rate and associated patient characteristics of liver disease in Wales 2004–2022: a retrospective population-scale observational study by Ashley Akbari, Andrew Yeoman, Haroon Ahmed, Jingwei Gao, Aled Davies, Thomas Peter Ignatius Pembroke

“…A total of 79 992 individuals (72%) entered the cohort with the underlying aetiology of liver disease, including alcohol-related liver disease, non-alcoholic fatty liver disease (NAFLD), viral hepatitis, metabolic, haemochromatosis and autoimmune liver diseases. …”
Get full text

BMI trajectories are associated with NAFLD and advanced fibrosis via aging-inflammation mediation by Haiyang Peng, Zhibo Zhao, Jianping Gong, Kun He

“…Abstract Background As the global epidemic of obesity fuels metabolic conditions, the burden of nonalcoholic fatty liver disease (NAFLD) will become enormous. Abundant studies revealed the association between high body mass index (BMI) and NAFLD but overlooked the BMI patterns across life stages. …”
Get full text

Prevalence of digestive diseases in patients with excessive body weight and obesity (<i>according to data of polyclinic department of versatile clinic</i>) by I. R. Popova

“…Of diseases of digestive organs the most frequent were: non-alcoholic fatty liver disease (NAFLD) – 83,4 % (r=0,35, p&lt;0,001), non-alcoholic steatohepatitis (NASH) – 13,1% (r=0,14, p&lt;0,001), gallstone disease (GSD) – 41,8 % (r=0,05, p &lt;0,05); steatosis of the pancreas – 86,4% (r=0,20, р&lt;0,001). …”
Get full text

Kupffer Cells Promote the Differentiation of Adult Liver Hematopoietic Stem and Progenitor Cells into Lymphocytes via ICAM-1 and LFA-1 Interaction by Deping Meng, Yuhong Qin, Nan Lu, Keke Fang, Yuan Hu, Zhigang Tian, Cai Zhang

“…These findings provide important insight into understanding liver extramedullary hematopoiesis and its significance, particularly under the state of some liver diseases, such as hepatitis, nonalcoholic fatty liver disease (NAFLD), and hepatocellular carcinoma (HCC).…”
Get full text

Влияние курсового приема L-орнитин- L-аспартата на фиброз и стеатоз печени у больных ассоциированной с нарушениями метаболизма жировой болезнью печени (неалкогольной жировой болезн... by Е. V. Garanina

“…Hyperammonaemia develops both in cirrhosis and earlier fibrotic stages during metabolic-associated fatty liver disease (MAFLD). Besides neurotropic, ammonia exerts the hepatotoxic and profibrotic effects. …”
Get full text

Correlation between Helicobacter pylori Infection and Metabolic Abnormality in General Population: A Cross-Sectional Study by Li-juan Lu, Ning-Bo Hao, Jian-Jun Liu, Xue Li, Rui-Ling Wang

“…For each individual, the following data were collected: age, gender, alanine transaminase (ALT), total protein, albumin, cholesterol, triglyceride (TG), high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C), urea nitrogen, creatinine, uric acid, fasting plasma glucose, postprandial blood sugar, nonalcoholic fatty liver disease (NAFLD), and bone mineral density (BMD). …”
Get full text

Assessing the health and economic burden of obesity-related complications in East-Asian populations: implementation of risk equations in the Core Obesity Model for Japan and model... by Ichiro Tatsuno, Mark Lamotte, Laetitia Gerlier, Anamaria-Vera Olivieri, James Baker-Knight

“…We aimed to adapt the core obesity model (COM) to predict incidences of weight-associated diseases, including type 2 diabetes, acute coronary syndrome (ACS), stroke, cancers, sleep apnoea, hyperuricaemia/gout, total knee replacement (TKR) and non-alcoholic fatty liver disease (NAFLD) in a Japanese population.Methods and analysis Literature was searched to identify studies reporting the association between risk factors and comorbidities in Japanese populations. …”
Get full text

Effect of Liraglutide on Serum TSH Levels in Patients with NAFLD and its Underlying Mechanisms by JiaoJiao Ye, Jing Xu, WenJie Wen, Bin Huang

“…Meanwhile, the control group included 49 patients with T2DM but without nonalcoholic fatty liver disease (NAFLD) who were matched for age and sex (baseline from July 2016 to June 2021). …”
Get full text

A New Hope for the Patients of Non‐Alcoholic Steatohepatitis: FDA Gives Green Signal for Resmetirom Use by Abdul Haseeb Hasan, Muhammad Ali Abid, Muhammad Hafi Abid, Laiba Suhail, Abubakar Nazir

“…ABSTRACT Background and Aims Non‐Alcoholic Steatohepatitis (NASH), a severe form of Non‐Alcoholic Fatty Liver Disease (NAFLD), is characterized by inflammation and fibrosis in the liver, often progressing to cirrhosis and hepatocellular carcinoma. …”
Get full text

Liraglutide Attenuates Hepatic Oxidative Stress, Inflammation, and Apoptosis in Streptozotocin-Induced Diabetic Mice by Modulating the Wnt/β-Catenin Signaling Pathway by Jie Yu, Yuan Zhao, Lingling Xu, Wei Li, Huabing Zhang, Fan Ping, Yuxiu Li

“…The results of the present study suggested that liraglutide improves T1DM-induced liver injury and may have important implications for the treatment of nonalcoholic fatty liver disease (NAFLD) in patients with T1DM.…”
Get full text